INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $948,006 | +16.3% | 51,133 | -30.6% | 0.05% | +18.2% |
| Q2 2023 | $814,989 | +26.9% | 73,688 | +54.1% | 0.04% | +10.0% |
| Q1 2023 | $642,330 | +121.5% | 47,828 | +690.4% | 0.04% | +150.0% |
| Q2 2020 | $290,000 | -11.0% | 6,051 | +16.8% | 0.02% | -33.3% |
| Q1 2020 | $326,000 | -64.2% | 5,180 | -29.4% | 0.02% | -40.0% |
| Q4 2019 | $910,000 | +114.1% | 7,341 | +14.5% | 0.04% | +90.5% |
| Q3 2019 | $425,000 | -16.5% | 6,409 | +0.2% | 0.02% | -12.5% |
| Q2 2019 | $509,000 | -25.6% | 6,399 | +4.7% | 0.02% | -27.3% |
| Q1 2019 | $684,000 | +12.3% | 6,114 | +1.1% | 0.03% | -13.2% |
| Q4 2018 | $609,000 | -35.6% | 6,047 | -19.2% | 0.04% | +5.6% |
| Q3 2018 | $946,000 | +73.6% | 7,488 | +15.2% | 0.04% | +63.6% |
| Q2 2018 | $545,000 | +49.3% | 6,499 | +9.4% | 0.02% | +46.7% |
| Q1 2018 | $365,000 | -4.9% | 5,940 | -9.6% | 0.02% | 0.0% |
| Q4 2017 | $384,000 | -10.3% | 6,569 | -11.0% | 0.02% | -16.7% |
| Q3 2017 | $428,000 | -47.9% | 7,382 | +8.7% | 0.02% | -51.4% |
| Q2 2017 | $822,000 | +0.9% | 6,793 | -5.7% | 0.04% | +2.8% |
| Q1 2017 | $815,000 | -3.8% | 7,202 | -7.7% | 0.04% | -7.7% |
| Q4 2016 | $847,000 | -42.9% | 7,800 | -13.4% | 0.04% | -45.1% |
| Q3 2016 | $1,483,000 | +10.0% | 9,009 | -4.6% | 0.07% | +7.6% |
| Q2 2016 | $1,348,000 | +7.8% | 9,446 | -2.9% | 0.07% | +1.5% |
| Q1 2016 | $1,250,000 | -30.9% | 9,730 | -19.7% | 0.06% | -24.4% |
| Q4 2015 | $1,809,000 | -9.5% | 12,113 | +0.5% | 0.09% | -24.6% |
| Q3 2015 | $1,998,000 | -19.1% | 12,048 | +17.7% | 0.11% | +11.8% |
| Q2 2015 | $2,471,000 | -9.5% | 10,236 | +5.7% | 0.10% | -3.8% |
| Q1 2015 | $2,731,000 | +117.1% | 9,685 | +20.1% | 0.11% | +103.8% |
| Q4 2014 | $1,258,000 | -26.0% | 8,062 | +12.3% | 0.05% | -35.0% |
| Q3 2014 | $1,699,000 | – | 7,179 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |